Nanoemulsion based lipid nanoparticles for effective demethylcantharidin delivery to cure liver cancer

IF 3.2 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Zijun Yan, Ting Yu, Xiaoping Wu, Mengyue Deng, Panpan Wei, Ning Su, Yuzhen Ding, Die Xia, Yuehui Zhang, Liangming Zhang, Tong Chen
{"title":"Nanoemulsion based lipid nanoparticles for effective demethylcantharidin delivery to cure liver cancer","authors":"Zijun Yan,&nbsp;Ting Yu,&nbsp;Xiaoping Wu,&nbsp;Mengyue Deng,&nbsp;Panpan Wei,&nbsp;Ning Su,&nbsp;Yuzhen Ding,&nbsp;Die Xia,&nbsp;Yuehui Zhang,&nbsp;Liangming Zhang,&nbsp;Tong Chen","doi":"10.1111/cbdd.14580","DOIUrl":null,"url":null,"abstract":"<p>Demethylcantharidin (DEM) is a widely used antitumor drug; however, its poor tumor targeting and serious organotoxicity limit its application. The aim of this study was to develop a new drug delivery system for efficient delivery of DEM. Nanoemulsion based lipid nanoparticles containing demethylcantharidin (DNLNs) were prepared by loading nanoemulsions into lipid nanoparticles. The cells proliferation, apoptosis, cycle, and uptake were investigated by Cell counting kit-8 (CCK-8), flow cytometry, and in situ fluorescence assays, respectively. Then, we established the H22 tumor-bearing mouse model to evaluate the antitumor efficacy of DNLNs and further studied its organ toxicity and distribution. DNLNs significantly inhibited the proliferation and promoted apoptosis of H22 cells, and H22 cells could take up more DNLNs. Compared with DEM, DNLNs had certain tumor-targeting properties, and the tumor inhibition rate increased by 23.24%. Moreover, DNLNs can increase white blood cell count and reduce organ toxicity. This study paves the way for nanoemulsion-based lipid nanoparticle (NLNs)-efficient DEM delivery to treat liver cancer.</p>","PeriodicalId":143,"journal":{"name":"Chemical Biology & Drug Design","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical Biology & Drug Design","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cbdd.14580","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Demethylcantharidin (DEM) is a widely used antitumor drug; however, its poor tumor targeting and serious organotoxicity limit its application. The aim of this study was to develop a new drug delivery system for efficient delivery of DEM. Nanoemulsion based lipid nanoparticles containing demethylcantharidin (DNLNs) were prepared by loading nanoemulsions into lipid nanoparticles. The cells proliferation, apoptosis, cycle, and uptake were investigated by Cell counting kit-8 (CCK-8), flow cytometry, and in situ fluorescence assays, respectively. Then, we established the H22 tumor-bearing mouse model to evaluate the antitumor efficacy of DNLNs and further studied its organ toxicity and distribution. DNLNs significantly inhibited the proliferation and promoted apoptosis of H22 cells, and H22 cells could take up more DNLNs. Compared with DEM, DNLNs had certain tumor-targeting properties, and the tumor inhibition rate increased by 23.24%. Moreover, DNLNs can increase white blood cell count and reduce organ toxicity. This study paves the way for nanoemulsion-based lipid nanoparticle (NLNs)-efficient DEM delivery to treat liver cancer.

Abstract Image

基于纳米乳液的脂质纳米颗粒可有效递送去甲黄嘌呤以治疗肝癌。
去甲基桔梗素(DEM)是一种广泛应用的抗肿瘤药物,但其肿瘤靶向性差和严重的器官毒性限制了它的应用。本研究旨在开发一种新的给药系统,以高效递送去甲斑蝥素。研究人员将纳米乳液加入脂质纳米颗粒中,制备了含有去甲桔皮素的纳米乳液脂质纳米颗粒(DNLNs)。通过细胞计数试剂盒-8(CCK-8)、流式细胞仪和原位荧光检测法分别检测了细胞的增殖、凋亡、周期和吸收情况。然后,我们建立了H22肿瘤小鼠模型来评估DNLNs的抗肿瘤疗效,并进一步研究了其器官毒性和分布。DNLNs能明显抑制H22细胞的增殖并促进其凋亡,且H22细胞能吸收更多的DNLNs。与DEM相比,DNLNs具有一定的肿瘤靶向性,肿瘤抑制率提高了23.24%。此外,DNLNs还能增加白细胞数量,降低器官毒性。这项研究为基于纳米乳液的脂质纳米粒子(NLNs)高效递送DEM治疗肝癌铺平了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chemical Biology & Drug Design
Chemical Biology & Drug Design 医学-生化与分子生物学
CiteScore
5.10
自引率
3.30%
发文量
164
审稿时长
4.4 months
期刊介绍: Chemical Biology & Drug Design is a peer-reviewed scientific journal that is dedicated to the advancement of innovative science, technology and medicine with a focus on the multidisciplinary fields of chemical biology and drug design. It is the aim of Chemical Biology & Drug Design to capture significant research and drug discovery that highlights new concepts, insight and new findings within the scope of chemical biology and drug design.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信